不可切除Ⅲ期非小细胞肺癌的治疗原则及问题.ppt

不可切除Ⅲ期非小细胞肺癌的治疗原则及问题.ppt

  1. 1、本文档共77页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
不可切除Ⅲ期非小细胞肺癌的治疗原则及问题

/ Purpose This is a national, randomized, web-based, double-blind study to determine whether erlotinib (Tarceva) compared to placebo improves progression-free survival (PFS) for patients with inoperable, stage III NSCLC following concurrent docetaxel, carboplatin and thoracic radiotherapy. We hypothesize that the introduction of this orally active, well-tolerated agent following concurrent chemoradiation and prior to the emergence of drug resistance will prolong the progression-free survival by 40% (10 months → 14 months). Estimated Enrollment: 380 Study Start Date: May 2005 Estimated Study Completion Date: December 2012 Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure) concurrent chemoRT with docetaxel 20 mg/m2, carboplatin AUC=2 intravenously weekly for 6 wks with thoracic RT of at least 61 Gy in 33 fractions over 6.5 weeks 1: Experimental Tarceva 150mg Intervention: Drug: Erlotinib (tarceva) Drug: Erlotinib (tarceva) Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 5 years of therapy. 2: Placebo Comparator Matched Placebo Intervention: Drug: Placebo Drug: Placebo Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 5 years of therapy. * Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28:43–48. 入选患者:不可手术切除的III期NSCLC 非鳞癌 无心包及肋膜转移 年龄18 有可评价病灶 未接受治疗(生物,化疗,放疗) ECOG0-1分 The non–small-cell lung cancer trial included patients with unresectable stage III nonsquamous non–small-cell hi

文档评论(0)

zhuwenmeijiale + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

版权声明书
用户编号:7065136142000003

1亿VIP精品文档

相关文档